Tardive dyskinesia (TD) is a type of dyskinesia, which is challenging to treat. TD is a nerve disorder with typical symptoms such as involuntary movements of lips, jaw, and tongue. The disease is also characterized by individuals experiencing involuntary movement of the upper and lower extremities and also breathing-choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to disability and can further stigmatize patients with mental illness.
Get FREE Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/218
Tardive akathisia, a type of tardive dyskinesia, involving inner tension, anxiety, acute pain, and compulsive drive to move the body. Generally, patients with prolonged exposure to antipsychotic drugs for neurological disorders such anxiety and depression are more likely to have tardive dyskinesia. In spite of various studies conducted by pharmaceutical companies to know the exact treatment mechanism for tardive dyskinesia, only one drug developed by Neurocrine Biosciences that has received approval. Strong pipeline drugs for treatment of TD disorder are expected to propel growth of the tardive dyskinesia drugs market.
Increasing incidence of neurological disorders is expected to drive growth of the global tardive dyskinesia drugs market during the forecast period
According to Mental Health America, the occurrence of tardive dyskinesia is estimated to be 10 to 20% of patients who are earlier treated with long term anti-psychotic medications. According to Neurocrine’s Chief Medical Officer, Chris O’Brien, all doctors and psychiatrists now accept Tardive dyskinesia as a prevalent condition. However, according to Neurocrine Bioscience, there are still an estimated 500,000 people in the U.S., who are affected by Tardive Dyskinesia each year.
However, low awareness on TD and its medication can hinder growth of global tardive dyskinesia drugs market.
Valbenazine is expected to hold dominant position in the global tardive dyskinesia drugs market over the forecast period.
Among regions, North America is expected to account for the largest share in the global tardive dyskinesia drugs market during the forecast period. For instance, according to Virtual Medical Center, Australia, tardive dyskinesia is observed in around 15-30% of patients in the U.S. who have been prescribed with long-term neuroleptic drugs administration. Patients with mood disorders such as depression, anxiety disorders, and bipolar affective disorder are at greater risk of developing tardive dyskinesia as compared to people suffering from schizophrenia. The symptoms of tardive dyskinesia will remit within 3 months of stopping neuroleptic drugs for 1 in 3 patients with tardive dyskinesia. Thus, the increase in prevalence of mental disorders would boost the tardive dyskinesia drugs market growth.
𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞!
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐨 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐭𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/218
Key companies operating in the global tardive dyskinesia drugs market are Valeant Pharmaceuticals, Neurocrine Biosciences, and Teva Pharmaceutical Industries.
Major companies in the market are focused on various growth strategies such as gaining product approvals from regulatory authorities, in order expand their product portfolio. For instance, in April 2017, Neurocrine Biosciences, Inc., a biopharmaceutical company, received the U.S. Food and Drugs Administration approval for Ingrezza capsules, which are indicated for the treatment of adults suffering from tardive dyskinesia.
Key players in the market are involved in various business strategies such as gaining product approvals from regulatory authorities, in order to enhance their market presence. For instance, in August 2017, Teva Pharmaceutical Industries received the U.S. FDA approval for AUSTEDO tablets, which is indicated for the treatment of patients suffering from tardive dyskinesia.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/218
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Tardive Dyskinesia Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Tardive Dyskinesia Drugs Industry Impact
Chapter 2 Global Tardive Dyskinesia Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Tardive Dyskinesia Drugs (Volume and Value) by Type
2.3 Global Tardive Dyskinesia Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Tardive Dyskinesia Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Tardive Dyskinesia Drugs Market Analysis
Chapter 6 East Asia Tardive Dyskinesia Drugs Market Analysis
Chapter 7 Europe Tardive Dyskinesia Drugs Market Analysis
Chapter 8 South Asia Tardive Dyskinesia Drugs Market Analysis
Chapter 9 Southeast Asia Tardive Dyskinesia Drugs Market Analysis
Chapter 10 Middle East Tardive Dyskinesia Drugs Market Analysis
Chapter 11 Africa Tardive Dyskinesia Drugs Market Analysis
Chapter 12 Oceania Tardive Dyskinesia Drugs Market Analysis
Chapter 13 South America Tardive Dyskinesia Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Tardive Dyskinesia Drugs Business
Chapter 15 Global Tardive Dyskinesia Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027